NHLBI TOPMed: Genetics of Asthma in Latino Americans (GALA)

This is a case pharmacogenetic study of bronchodilator drug response (Albuterol) among racially admixed Latino children with asthma between the ages of 8-40. Lung function testing was performed using the KoKo PFT system and each participant was administered albuterol dependent on age. Participants under 16 years of age, were administered 2 puffs of albuterol from a standard metered dose inhaler and 4 puffs for participants over 16 years old. The overall goal is to identify genetic factors which are predictive of drug response in children with asthma. The principal tools include a questionnaire and biological specimen collection. Participants with asthma have physician-diagnosed asthma, symptoms and medications.]]>
TOPMed Whole Genome Sequencing Methods: Freeze 8TOPMed Whole Genome Sequencing Methods: Freeze 9 Eligibility Subjects meeting the following criteria will be eligible for participation: 8 - 40 years of age Mexican or Puerto Rican descent [self-identified] History of asthma [physician diagnosed or demonstration of 12% reversibility of FEV1 by spirometry] Having experienced symptoms of coughing, wheezing or shortness of breath in the past 2 years No respiratory infections for ≥ 6 weeks No asthma exacerbations for ≥ 6 weeks ≤ 10 pack year smoking history, no smoking in the last year If pregnant, < 3rd trimester ]]>
Time Line 2001 - First qualifying participant 2017 - Whole Genome Sequencing ]]>